Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthritis: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease

L M J Helenius, J H Hietanen, I Helenius, H Kautiainen, H Piirainen, L Paimela, M Lappalainen, R Suuronen, C Lindqvist, M Leirisalo-Repo

Abstract

Objectives—To investigate the occurrence of and risk factors for focal sialadenitis in patients with rheumatoid arthritis (RA), mixed connective tissue disease (MCTD), ankylosing spondylitis (AS), and spondyloarthritis (SpA).

Methods—A total of 85 patients (25 with RA, 19 with MCTD, 19 with AS, 22 with SpA) participated in the study. Each patient filled out a questionnaire for eye and oral symptoms and for the use of medication, and was interviewed; other tests included Schirmer’s test, laboratory tests, collection of unstimulated and stimulated whole saliva, and minor salivary gland biopsy. A focus score of ≥1 was regarded as an indicator of focal sialadenitis.

Results—Focal sialadenitis was observed in 68% (57/84) of all patients. It affected 80% (20/25) of the patients with RA, 94% (17/18) of those with MCTD, 58% (11/19) of those with AS, and 41% (9/22) of those with SpA (χ² test, p=0.0013). Salivary secretion correlated negatively with the focus scores—that is, severity of focal sialadenitis. Patients with focal sialadenitis had both decreased salivary secretion and decreased tear secretion significantly more often than did patients without (χ² test, p=0.0074 and p=0.048 respectively). Patients with positive rheumatoid factor (RF), antinuclear antibodies (ANA), or SSA or SSB antibodies had sialadenitis significantly more often than did patients with negative antibodies. In the subgroup of patients with AS or SpA, no associations were found between focal sialadenitis and the presence of these antibodies.

Conclusion—In addition to patients with RA or MCTD, focal sialadenitis also affects a very high proportion of patients with AS or SpA. Focus scores are significantly higher in patients with RA or MCTD than in those with AS or SpA. A significant association exists between focal sialadenitis and RF, ANA, SSA and SSB. However, in the subgroup of patients with AS or SpA, no associations were found between focal sialadenitis and serological markers or clinical symptoms.
Focal sialadenitis and rheumatic diseases

Table 1  Characteristics of the study groups

<table>
<thead>
<tr>
<th></th>
<th>Rheumatoid arthritis (n=25)</th>
<th>Mixed connective tissue disease (n=19)</th>
<th>Ankylosing spondylitis (n=19)</th>
<th>Spondyloarthropathy (n=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>2/23</td>
<td>1/18</td>
<td>13/6</td>
<td>13/9</td>
</tr>
<tr>
<td>Mean (SD) age (years)</td>
<td>49.3 (11.2)</td>
<td>46.3 (15.5)</td>
<td>42.1 (11.4)</td>
<td>38.3 (9.8)</td>
</tr>
<tr>
<td>Mean (SD) duration of disease (years)</td>
<td>10.5 (2.6)</td>
<td>10.6 (11.9)</td>
<td>13.3 (8.9)</td>
<td>13.0 (9.2)</td>
</tr>
<tr>
<td>Peripheral arthritis*</td>
<td>25 (100)</td>
<td>16 (84)</td>
<td>14 (74)</td>
<td>21 (95)</td>
</tr>
<tr>
<td>History of use of*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>18 (72)</td>
<td>0 (0)</td>
<td>17 (89)</td>
<td>17 (77)</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>11 (44)</td>
<td>17 (89)</td>
<td>11 (58)</td>
<td>14 (64)</td>
</tr>
<tr>
<td>Laboratory tests†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive Sm</td>
<td>0 (0)</td>
<td>3 (16)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Positive RNP</td>
<td>0 (0)</td>
<td>11 (72)</td>
<td>11 (72)</td>
<td>11 (72)</td>
</tr>
<tr>
<td>Positive RF</td>
<td>17 (68)</td>
<td>12 (63)</td>
<td>3 (16)</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Positive SSA or SSB</td>
<td>0 (0)</td>
<td>11 (58)</td>
<td>1 (5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Positive ANA</td>
<td>11 (44)</td>
<td>19 (100)</td>
<td>5 (26)</td>
<td>6 (27)</td>
</tr>
<tr>
<td>Low C3</td>
<td>0 (0)</td>
<td>3 (16)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Low C4</td>
<td>2 (8)</td>
<td>5 (26)</td>
<td>2 (11)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Positive RNP</td>
<td>0 (0)</td>
<td>11 (58)</td>
<td>0 (0)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Positive Sm</td>
<td>0 (0)</td>
<td>3 (16)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

*Number of patients (%); †Number of patients with abnormal test result (%).
RF = Rheumatoid factor; ANA = antinuclear antibodies; RNP = ribonuclear protein; Sm = Smith antigen.

Patients and methods

PATIENTS

Eighty five patients, consisting of 25 with RA, 19 with MCTD, 19 with AS, and 22 with SpA, volunteered to participate (table 1).

All patients gave their informed consent, and the study was approved by the ethics committee of Helsinki University Central Hospital.

All of the patients with RA fulfilled the American Rheumatism Association 1987 criteria,17 the patients with MCTD met the criteria for the diagnosis by Alarcon-Segovia,18 and the patients with AS fulfilled the modified New York criteria for definite ankylosing spondylitis.19 Other patients, with seronegative oligoarthritis or spondylitis not fulfilling the diagnostic criteria for AS, were grouped as patients with SpA and fulfilled the European Spondyloarthritis Study Group criteria.20

STUDY DESIGN

The study was carried out from September 1996 to August 1997. All consecutive patients with MCTD, AS, or SpA treated at the Outpatient Department of Rheumatology of Meilahti Hospital, Helsinki University Central Hospital, were asked to participate in the study between September 1996 and March 1997. During the same time, patients in a continuing prospective study of early RA started in 1986–1989 were also asked to participate. The patients were asked to participate irrespective of the presence of oral or ocular symptoms. All patients asked to participate initially gave their informed consent, but later three (one with MCTD, one with AS, and one with SpA) withdrew their consent.

All patients filled out a questionnaire on eye and oral symptoms according to the European Community Study Group Diagnostic Criteria for Sjögren’s syndrome,21 with the following modifications. For the ocular symptoms, the question about persistent or recurrent tear gland involvement was omitted, and a question about drugs with potential to cause decreased salivary flow was added. The replies were also checked in personal interviews (conducted by L M J H). The use of drugs over the whole disease period and the use of disease modifying antirheumatic drugs, other drugs for chronic diseases, and antidepressants—for example, antihypertensive, sedative, anticholinergic—were recorded. Because of the immunomodulating properties of sulfasalazine and prednisolone, we also collected data on the use of these drugs. The patients were divided into three groups: no sulfasalazine treatment at all or use for less than three months; sulfasalazine treatment for 3–11 months; sulfasalazine treatment for a year or longer. We also recorded whether or not the patient was on sulfasalazine at the time of examination. The patients were also divided into two groups according to the use of corticosteroids: those currently on corticosteroids or who had stopped the treatment less than three months ago (current use) and those without previous use of corticosteroids or if the treatment had been withdrawn more than three months ago.

CLINICAL EXAMINATION

Schirmer’s test was performed using standardised tear strips (Clement Clarke, Edinburgh, UK), placed for five minutes on the conjunctiva at the most lateral part of the inferior lid, without previous use of anaesthetic eyedrops. The patients sat with their eyes closed, but not shut tight. After five minutes, the length of the wetted area of the strip was measured, starting from the notch corresponding to the inferior lid margin; 5 mm of wetted paper per five minutes was considered the lower limit of the normal value.22

Unstimulated and stimulated saliva secretion tests were performed between 8 am and 2 pm; the patients fasted and were not allowed to brush their teeth, rinse their mouths, or smoke for at least one hour before the procedures. During the tests, the patients were seated, inclining slightly forward. Saliva was collected in conical calibrated tubes; stimulation was induced by movement chewing on a 2 g paraffin block. Collection time was five minutes for both the unstimulated and stimulated tests. Saliva secreted during the first 30 seconds was
Table 2  Results of minor salivary gland biopsies, and of Schirmer’s and salivary secretion tests

<table>
<thead>
<tr>
<th></th>
<th>RA (n=25)</th>
<th>MCTD (n=19)</th>
<th>AS (n=19)</th>
<th>SpA (n=22)</th>
<th>p Value between groups*</th>
<th>Post hoc testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal sialadenitis</td>
<td>20 (80)</td>
<td>17 (94)§</td>
<td>11 (58)</td>
<td>9 (41)</td>
<td>0.001</td>
<td>RA&gt;SpA, MCTD&gt;AS, MCTD&gt;SpA</td>
</tr>
<tr>
<td>Decreased salivary secretion†</td>
<td>3 (12)</td>
<td>11 (61)</td>
<td>4 (22)</td>
<td>0 (0)</td>
<td>&lt;0.001</td>
<td>RA&lt;MCTD, MCTD&gt;SpA</td>
</tr>
<tr>
<td>Oral symptoms</td>
<td>11 (44)</td>
<td>14 (74)</td>
<td>8 (42)</td>
<td>3 (14)</td>
<td>0.002</td>
<td>MCTD&gt;SpA</td>
</tr>
<tr>
<td>Decreased tear secretion‡</td>
<td>11 (44)</td>
<td>13 (87)</td>
<td>6 (32)</td>
<td>3 (15)</td>
<td>0.021</td>
<td>MCTD&gt;SpA</td>
</tr>
<tr>
<td>Ocular symptoms</td>
<td>13 (52)</td>
<td>12 (63)</td>
<td>10 (53)</td>
<td>10 (45)</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td>Patients with Sjögren’s syndrome¶</td>
<td>7 (28)</td>
<td>11 (73)</td>
<td>5 (26)</td>
<td>3 (15)</td>
<td>0.021</td>
<td>RA&lt;MCTD, MCTD&gt;AS, MCTD&gt;SpA</td>
</tr>
</tbody>
</table>

*χ² test.
†Either unstimulated or stimulated salivary excretion abnormal. Not studied in four patients with MCTD, two with SpA, and one with AS.
‡One minor salivary gland biopsy sample was not representative and was therefore excluded.
§Not studied in four patients with MCTD and two with SpA.
¶Fulfilling the European criteria for secondary Sjögren’s syndrome.⁵

RA = Rheumatoid arthritis; MCTD = mixed connective tissue disease; AS = ankylosing spondylitis; SpA = spondyloarthropathy.

Table 3  Patients on medication that decreased secretion of saliva or tears

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Sex (M/F)</th>
<th>Disease</th>
<th>Focal sialadenitis</th>
<th>Medication</th>
<th>Positive Schirmer’s test</th>
<th>Decreased salivary secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>F</td>
<td>RA</td>
<td>+</td>
<td>Carbamazepine</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>63</td>
<td>F</td>
<td>RA</td>
<td>+</td>
<td>Chlorothiazide, amiloride</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>52</td>
<td>F</td>
<td>RA</td>
<td>+</td>
<td>Chlorothiazide, amiloride</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>47</td>
<td>F</td>
<td>RA</td>
<td>+</td>
<td>Amitriptyline</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>71</td>
<td>F</td>
<td>RA</td>
<td>+</td>
<td>Chlorothiazide, amiloride</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>67</td>
<td>F</td>
<td>MCTD</td>
<td>+</td>
<td>Amitriptyline</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>63</td>
<td>F</td>
<td>SpA</td>
<td>+</td>
<td>Hydrochlorothiazide, amiloride</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>54</td>
<td>M</td>
<td>AS</td>
<td>–</td>
<td>Amitriptyline, flupentixol</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

RA = Rheumatoid arthritis; MCTD = mixed connective tissue disease; AS = ankylosing spondylitis; SpA, spondyloarthropathy.
patients with MCTD and least often in patients with SpA ($\chi^2$ test, $p<0.001$; table 2). Decreased tear secretion occurred most often in patients with MCTD and least often in patients with SpA ($\chi^2$ test, $p = 0.021$; table 2). Eight of the 85 patients (9%) currently used medication that decreased either salivary or tear secretion$^{25}$ (table 3). Three had decreased salivary secretion, and all had decreased tear secretion. None of the subjects experienced major adverse effects from the labial salivary gland biopsy. One patient had a large haematoma, one experienced transiently decreased sensation in a small area in the lower lip, and, in another, there was excessive scar formation. One biopsy sample (patient with MCTD) was not representative and was therefore excluded from further analysis.

HISTOLOGICAL EXAMINATION

Focal sialadenitis was observed in 68% (57/84) of all patients. It affected 80% (20/25) of those with RA, 94% (17/18) of those with MCTD, 58% (11/19) of those with AS, and 41% (9/22) of those with SpA ($\chi^2$ test, $p=0.0013$; table 2). The median focus scores differed significantly among the study groups, being highest (4.1) in the MCTD group and lowest (<1) in the SpA group (Kruskall-Wallis, $p<0.0001$; fig 1).

ASSOCIATION BETWEEN FOCAL SIALADENITIS AND CLINICAL FINDINGS

Patients with focal sialadenitis more often had both decreased salivary secretion (30% vs 4%; $\chi^2$ test, $p=0.0074$) and decreased tear secretion (58% vs 35%; $\chi^2$ test, $p=0.048$) than patients without it. Focus scores correlated negatively with the amount of both unstimulated and stimulated saliva secretion (Spearman rank correlation test, $r_s=-0.46$, 95% CI $-0.27$ to $-0.61$; and $r_s=-0.51$, 95% CI $-0.33$ to $-0.65$ respectively). Focal sialadenitis tended to occur more often in women (41/55) than in men (16/29) ($\chi^2$ test, $p=0.071$). In the multiple logistic regression model, increasing age and the MCTD group were independent risk factors for focal sialadenitis (table 4). No associations were observed between focal sialadenitis and disease duration or the use of corticosteroids or sulfasalazine (data not shown).

ASSOCIATION BETWEEN FOCAL SIALADENITIS AND LABORATORY VARIABLES

Patients with RF had focal sialadenitis significantly more often than patients without it ($\chi^2$ test, $p=0.002$). Patients with focal sialadenitis had higher RF titres than those without it (Mann-Whitney, $p<0.001$). Similarly, patients with positive ANA, SSA, or SSB had sialadenitis more often than patients without these antibodies ($\chi^2$ test, $p=0.0041$, 0.013, and 0.077 respectively). No associations were observed between focal sialadenitis and low complement levels or the presence of RNP or Sm antibodies. HCV antibodies were negative in all the patients tested.

SERONEGATIVE ARTHRITIS

The subgroup of patients with AS or SpA was further analysed for risk factors for sialadenitis. The presence of focal sialadenitis was not associated with decreased salivary or tear secretion, the clinical type of disease (axial or peripheral arthritis), age, the use of medication (corticosteroids or sulfasalazine), disease duration, or the presence of ANA, ENA, SSA, SSB, RNP, Sm antibodies, positive RF$^{5}$ or low complement levels (data not shown).

Discussion

Focal sialadenitis was common in patients with various rheumatic diseases, being most common in those with MCTD, but also surprisingly common in those with AS or SpA. Focal sialadenitis was significantly associated with decreased secretion of saliva and tears. Significant associations were observed between focal sialadenitis and RF and its titre: ANA, and SSA and SSB antibodies. This observation was confined to patients with RA or MCTD. Increasing age and MCTD were independent risk factors for focal sialadenitis. No associations were
observed between focal sialadenitis and disease duration or the use of corticosteroids or sulfasalazine.

VALIDITY OF THE DATA
The patients were chosen randomly. Salivary gland biopsy specimens of the lower lip were taken in a standard way. All of the specimens were representative except one, which was excluded. All patients were studied at the same time of day, and all of the tests were performed by one person with the same materials. It is possible that medication may have influenced the results on salivary or tear secretion, but this was carefully recorded. The use of sulfasalazine and corticosteroids had no effect on the occurrence of focal sialadenitis within each of the study groups.

The biopsy procedure described here for labial salivary gland is safe and effective if it is performed through clinically normal mucosa, if the specimen contains enough separate glands for interpretation, and if the histopathological examination includes determination of a focus score.26 Focal sialadenitis in an adequate labial salivary gland specimen and is said to have good specificity and sensitivity for Sjögren’s syndrome when the focus score is at least 1.21 However, patients with Sjögren’s syndrome can have a normal focus score with advanced disease27 or focal sialadenitis with normal salivary flow,27 indicating low specificity and sensitivity of the histological procedure in the diagnosis of Sjögren’s syndrome.

COMPARISON WITH PREVIOUS DATA
Our results confirm previous findings on the high prevalence of focal sialadenitis and decreased salivary excretion in patients with MCTD.23–28 Konttin et al.25 observed focal sialadenitis in nine and decreased salivary excretion in seven of ten patients with MCTD. These are comparable to the 94% and 61% prevalence rates respectively observed in our 18 patients with MCTD. In the present study, 80% of the patients with RA had focal sialadenitis, and 40% had sialadenitis combined with decreased salivary or tear secretion. These values are higher than those of Andonopoulou et al.,1 who found focal sialadenitis in 31% and sialadenitis combined with clinical manifestations of Sjögren’s syndrome in 24% of patients with RA. The difference can be explained by the scoring systems. Andonopoulou et al. used Tarpley’s classification20 from 1974, which accepts a higher number of inflammatory cell aggregates as pathological compared with the presently widely used scoring system applied by us. In agreement with previous work,1 10–26 the focus scores in our patients with focal sialadenitis in association with MCTD or RA were distinctly abnormal. This contrasts with the small increase in the scores in patients with AS or SpA. Thus, although abnormal scores occurred in all the patient groups, patients with MCTD or RA differed distinctly from those with AS or SpA.

In the normal population, both tear secretion and salivary secretion are physiologically reduced in the elderly.21 Vitali et al.31 found that the presence of inflammatory foci in lip biopsy specimens of patients without Sjögren’s syndrome did not correlate with age, whereas Syrjänen32 observed that foci of inflammatory cells increased with age, as well as with acinar atrophy, ductal dilatation, and degree of fibrosis, among 78 healthy people. Disease duration did not correlate with focal sialadenitis in the present study, which is in accordance with the findings of Gerli et al.33

In patients with RA, the presence of ANA was observed in 44%, a value comparable to that in the literature,33 while SSA/SSB antibodies were not present in RA. SSA/SSB antibodies are most common in patients with primary Sjögren’s syndrome and systemic lupus erythematosus,33 but occur less often in patients with RA.34 In accordance with previous reports,36–37 we observed SSA/SSB antibodies in 58% of the patients with MCTD. We used immunodiffusion to measure these antibodies. Immunodiffusion is less sensitive than enzyme linked immunosorbent assay (ELISA) for detecting SSA and SSB antibodies.34 Immunodiffusion detected these antibodies only in 0–2% of patients with RA, whereas the prevalence was 22–28% when measured by ELISA.36 The antibody levels have been shown to change in association with the disease activity of patients with Sjögren’s syndrome and systemic lupus erythematosus.36 The absence of SSA and SSB antibodies is further evidence for poor agreement between histology and autoantibodies, as discussed previously.35

In accordance with the findings of Saito et al.,36 we observed an association between the presence of RF, ANA, SSA, or SSB and focal sialadenitis in biopsy samples of labial salivary gland. Patients with focal sialadenitis also had higher titres of RF than patients without sialadenitis. Shah et al.40 and Gerli et al.41 also found significant associations between focal sialadenitis in biopsy specimens of labial salivary gland and the presence of ANA, SSA, and SSB antibodies. An autoimmune focal sialadenitis, as confirmed by high focus scores in biopsy specimens of labial salivary gland in the present study, seems to be the most likely reason for decreased salivary secretion in patients with MCTD or RA.

A few studies have investigated the occurrence of focal sialadenitis in patients with AS or SpA.13–14 42 In the present study, 58% of the patients with AS and 41% of those with SpA had focal sialadenitis. Whaley et al.43 observed a distinct (grade III) focal sialadenitis in two of 12 patients with AS, neither of whom had decreased salivary or tear secretion. Brandt et al.3 found a definite focal sialadenitis (focus scores 2–13) in seven (7%) of 105 patients with SpA or AS. However, Brandt et al.3 collected samples only from patients who had a combination of both symptoms of dry mouth and/or eyes and positive ANA. The difference in prevalence of focal sialadenitis between our study and those of Whaley et al. and Brandt et al. can be explained by the different criteria for the definition of abnormal focus score. We accepted all patients with the focus score of ≥1, as suggested by the present
criteria.22 Despite the high occurrence of focal sialadenitis in the SpA group, none showed decreased salivary secretion, and the median focus score was quite low, suggesting that the sialadenitis was mild in this group. However, 23% of the patients with SpA had decreased tear secretion. The moderately increased focus scores observed in AS and SpA may be an indicator of mild sialadenitis. They can also be interpreted as reflecting poor specificity of focus scores, because of the low association with clinical findings.23 On the other hand, the focus score may be increased before the development of oral symptoms,24 indicating a need for follow-up of the patients with abnormal focus scores in the present study.

In conclusion, focal sialadenitis affects a high proportion of patients with MCTD, RA, AS, or SpA. Its occurrence is significantly associated with RF, as well as with ANA, SSA and SSB antibodies. The association is most evident in RA and in MCTD. Because of the common problems in all the patient groups, the patients should be screened for ocular and oral symptoms, and, if symptomatic, should be referred for specialist care.

We are grateful to Professor Jukka Meurman, MD, DDS, for their valuable help in preparing the manuscript. We also thank Mrs Marjatta Kivekäs from the Dr Pekka Laine, DDS, for their valuable help in preparing the histological slides. The work was supported by Helsinki University Central Hospital Research Funds.

Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease

L M J Helenius, J H Hietanen, I Helenius, H Kautiainen, H Piirainen, L Paimela, M Lappalainen, R Suuronen, C Lindqvist and M Leirisalo-Repo

Ann Rheum Dis 2001 60: 744-749
doi: 10.1136/ard.60.8.744

Updated information and services can be found at:
http://ard.bmj.com/content/60/8/744

These include:

References
This article cites 41 articles, 6 of which you can access for free at:
http://ard.bmj.com/content/60/8/744#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)
Ankylosing spondylitis (417)
Calcium and bone (725)
Pathology (444)
Clinical diagnostic tests (1282)
Radiology (1113)
Surgical diagnostic tests (431)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/